MaaT Pharma to Showcase Key Data at EBMT Meeting as MaaT013 Awaits EMA Review
Event summary
- MaaT Pharma will present four abstracts at the 52nd EBMT Annual Meeting, including final results for MaaT013, its lead asset under EMA review.
- An oral presentation will detail overall survival data from the ARES Phase III trial for MaaT013 in treating steroid-refractory aGvHD.
- Three poster presentations will cover real-world outcomes in third-line aGvHD, and study designs for PHOEBUS and THRASSA trials.
- Clinigen will host an industry symposium on managing steroid-refractory aGvHD, featuring key hematology experts.
The big picture
MaaT Pharma’s participation in the EBMT meeting underscores its leadership in microbiome-driven therapies for hemato-oncology. The focus on MaaT013’s final data and pipeline advancements comes at a critical juncture as the company awaits EMA approval, which could validate its position in treating steroid-refractory aGvHD. The collaboration with Clinigen further strengthens its commercial strategy in Europe.
What we're watching
- Regulatory Approval
- Whether the EMA will approve MaaT013 based on the final ARES trial data presented at EBMT.
- Clinical Pipeline
- The progress of PHOEBUS and THRASSA trials, which could expand MaaT Pharma’s therapeutic pipeline.
- Commercial Strategy
- How Clinigen’s Early Access Program and commercialization efforts will impact MaaT013’s market penetration.
Related topics